Aileron Therapeutics Company Profile (NASDAQ:ALRN)

About Aileron Therapeutics (NASDAQ:ALRN)

Aileron Therapeutics logoAileron Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation. The Company is advancing its lead oncology program to deliver efficacy and safety in a spectrum of solid and hematological malignancies. Its lead product candidate, ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers. The Company is conducting an ongoing Phase I clinical trial of ALRN-6924 in adult patients with solid tumors or lymphomas expressing non-mutated or wild-type p53 that are refractory to or intolerant of standard therapy. ALRN-6924 may reactivate p53-mediated cell death by targeting both of the natural p53 suppressor proteins, Mouse double minute 2 homolog (MDM2) and MDMX.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ALRN
  • CUSIP: N/A
  • Web:
  • Market Cap: $199.83 million
  • Outstanding Shares: 14,715,000
Average Prices:
  • 50 Day Moving Avg: $13.23
  • 200 Day Moving Avg: $12.84
  • 52 Week Range: $10.37 - $15.48
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.26
  • P/E Growth: 0.00
  • Current Ratio: 2.19%
  • Quick Ratio: 2.19%
  • Average Volume: 50,311 shs.

Frequently Asked Questions for Aileron Therapeutics (NASDAQ:ALRN)

What is Aileron Therapeutics' stock symbol?

Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN."

When will Aileron Therapeutics make its next earnings announcement?

Aileron Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November, 9th 2017. View Earnings Estimates for Aileron Therapeutics.

Where is Aileron Therapeutics' stock going? Where will Aileron Therapeutics' stock price be in 2017?

4 equities research analysts have issued 1 year price targets for Aileron Therapeutics' shares. Their forecasts range from $19.00 to $20.00. On average, they anticipate Aileron Therapeutics' stock price to reach $19.33 in the next year. View Analyst Ratings for Aileron Therapeutics.

Who are some of Aileron Therapeutics' key competitors?

Who are Aileron Therapeutics' key executives?

Aileron Therapeutics' management team includes the folowing people:

  • Joseph A. Yanchik III, Esq., President, Chief Executive Officer, Director
  • Evan Lippman, Chief Financial Officer and Business Officer, Senior Vice President
  • Manuel C. Aivado, Senior Vice President and Chief Medical Officer
  • D. Allen Annis Ph.D., Vice President - Biophysical and Analytical Technologies
  • Seth L. Harrison M.D., Director

When did Aileron Therapeutics IPO?

(ALRN) raised $61 million in an initial public offering on Thursday, June 29th 2017. The company issued 3,800,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

How do I buy Aileron Therapeutics stock?

Shares of Aileron Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aileron Therapeutics' stock price today?

One share of Aileron Therapeutics stock can currently be purchased for approximately $13.58.

MarketBeat Community Rating for Aileron Therapeutics (NASDAQ ALRN)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  34 (Vote Outperform)
Underperform Votes:  27 (Vote Underperform)
Total Votes:  61
MarketBeat's community ratings are surveys of what our community members think about Aileron Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Aileron Therapeutics (NASDAQ:ALRN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $19.33 (42.37% upside)
Consensus Price Target History for Aileron Therapeutics (NASDAQ:ALRN)
Price Target History for Aileron Therapeutics (NASDAQ:ALRN)
Analysts' Ratings History for Aileron Therapeutics (NASDAQ:ALRN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/11/2017Canaccord GenuityReiterated RatingBuy$19.00LowView Rating Details
7/24/2017William BlairInitiated CoverageOutperform -> OutperformHighView Rating Details
7/24/2017Bank of America CorporationInitiated CoverageBuy -> Buy$19.00HighView Rating Details
7/24/2017Jefferies Group LLCInitiated CoverageBuy -> Buy$20.00HighView Rating Details
(Data available from 10/21/2015 forward)


Earnings History for Aileron Therapeutics (NASDAQ:ALRN)
Earnings by Quarter for Aileron Therapeutics (NASDAQ:ALRN)
Earnings History by Quarter for Aileron Therapeutics (NASDAQ ALRN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/8/2013Q3 2012($0.07)ViewN/AView Earnings Details
11/12/2012Q312($0.03)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Aileron Therapeutics (NASDAQ:ALRN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20172($0.44)($0.42)($0.43)
Q3 20172($0.36)($0.32)($0.34)
Q4 20172($0.39)($0.35)($0.37)
(Data provided by Zacks Investment Research)


Dividend History for Aileron Therapeutics (NASDAQ:ALRN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Aileron Therapeutics (NASDAQ:ALRN)
Insider Ownership Percentage: 68.10%
Institutional Ownership Percentage: 12.30%
Insider Trades by Quarter for Aileron Therapeutics (NASDAQ:ALRN)
Institutional Ownership by Quarter for Aileron Therapeutics (NASDAQ:ALRN)
Insider Trades by Quarter for Aileron Therapeutics (NASDAQ:ALRN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/5/2017Cvf, LlcMajor ShareholderBuy180,000$15.00$2,700,000.00View SEC Filing  
7/5/2017Lilly Ventures Fund I LlcInsiderBuy250,000$15.00$3,750,000.00View SEC Filing  
7/5/2017Reinhard J AmbrosDirectorBuy266,667$15.00$4,000,005.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Aileron Therapeutics (NASDAQ:ALRN)
Latest Headlines for Aileron Therapeutics (NASDAQ:ALRN)
DateHeadline logoZacks: Analysts Set $19.33 Target Price for Aileron Therapeutics, Inc. (ALRN) - October 16 at 12:52 PM logoBoston biotech developing obesity drug pulls down $120M in IPO - October 10 at 2:53 AM logoZacks: Aileron Therapeutics, Inc. (ALRN) Given $19.33 Average Price Target by Brokerages - October 7 at 6:50 PM logoAileron Therapeutics Added to the Russell 2000, Russell 3000 and Russell Microcap Indexes - September 19 at 3:46 PM logo Analysts Set $19.33 Target Price for Aileron Therapeutics Inc (ALRN) - September 18 at 6:38 PM logoTTOO Rallies For 2nd Day, SAGE's STATUS Flops, ICPT Warns Of Ocaliva Overdosing - September 13 at 4:56 PM logo Aileron Therapeutics, Inc. (ALRN) Receives Average Recommendation of "Strong Buy" from Brokerages - September 11 at 8:36 PM logo Aileron Therapeutics, Inc. (ALRN) Given Consensus Rating of "Strong Buy" by Brokerages - September 2 at 12:36 PM logoAileron Therapeutics (ALRN) Announces Presentation of Preclinical Data with ALRN-6924 at ISEH - August 25 at 1:33 AM logoAduro Biotech (ADRO) and AILERON THERAP (ALRN) Head-To-Head Analysis - August 21 at 10:26 AM logoAileron Therap (ALRN) Stock Rating Reaffirmed by Canaccord Genuity - August 11 at 6:20 PM logoAileron Therapeutics Reports Second Quarter 2017 Financial Results - August 10 at 5:10 PM logoAileron Therapeutics to Present at Canaccord Genuity 37th Annual Growth Conference - August 3 at 4:45 PM logoAILERON THERAP's (NASDAQ:ALRN) Quiet Period Will Expire on August 8th - August 1 at 12:28 PM logoAileron Therap (ALRN) Expected to Post Earnings of -$0.43 Per Share - July 31 at 6:32 PM logoEquities Analysts Set Expectations for Aileron Therap's Q2 2017 Earnings (NASDAQ:ALRN) - July 26 at 9:25 AM logoResearch Analysts Offer Predictions for Aileron Therap's Q2 2017 Earnings (ALRN) - July 26 at 9:24 AM logoAileron Therap (NASDAQ:ALRN) Earns Outperform Rating from Analysts at William Blair - July 24 at 11:01 AM logo[$$] Novartis, Glaxo and Lilly Bigly Back New Biotech - July 19 at 4:55 PM logoAileron Therap (NASDAQ:ALRN) Insider Lilly Ventures Fund I. Llc Acquires 250,000 Shares - July 7 at 10:42 PM logoAileron Therapeutics Announces Pricing of Initial Public Offering - July 7 at 5:28 AM logoHere's the Latest on Four New Biotech IPOs - July 7 at 5:28 AM logoAileron Therapeutics Inc (ALRN) Director Buys $4,000,005.00 in Stock - July 5 at 10:24 PM logoAileron Therapeutics Inc (ALRN) Major Shareholder Acquires $2,700,000.00 in Stock - July 5 at 10:22 PM



Aileron Therapeutics (ALRN) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.